APH vs PMCB · P/E 40, rev $23.09B vs $8.6M cap
Amphenol Corporation (APH) versus PharmaCyte Biotech Inc (PMCB) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported PMCB revenue for 2025-04-30 was $0. Net income was $30.7M. PMCB currently screens at market cap $8.6M.
APH currently screens at market cap $170.77B and trailing P/E 39.9. PMCB currently screens at market cap $8.6M.
Not investment advice. Open the APH and PMCB stock pages for the full models.
Not investment advice.